Course Finder

Research Assistant: Engineering Antibody Drug Conjugates for Cancer Therapy


Introduction to the topic:

This research project, conducted at Immunordic, a biotech company located near DIS, focuses on developing a therapeutic approach to accelerate drug discovery and cancer immunotherapy.

The main goal is to engineer and validate novel VHH-based antibody drug conjugates (ADCs). ADCs are antibodies linked to cytotoxic drugs. They are designed to selectively target and kill cancer cells in solid tumors. The project aims to generate highly selective therapeutic lead candidates with commercialization potential as a service model for biotech and pharmaceutical companies worldwide.

Project details:

The first phase of the project involves designing modular, peptide-based cytotoxic payloads and antibody linkers, which will be computationally evaluated for potency, stability, and selectivity.

Next, genetic constructs encoding the most promising ADCs will be designed and cloned into bacterial expression systems. These constructs will then be introduced into a high-efficiency bacterial production strain, and proper assembly will be verified through Sanger sequencing.

In the third phase, the focus shifts to upscaling ADC production. Optimized conditions will be established for large-scale (0.5L) bacterial synthesis, followed by purification and quality control. Finally, the toxic effect of the ADCs will be tested using in vitro cancer cell assays.

The project will run across multiple semesters, with each term focused on specific research goals. As a Research Assistant, you will contribute to a particular phase of the project depending on when you join. Activities will include both literature studies and hands-on lab work, such as bacterial cloning, protein purification, cancer cell culture, or assay development.

This structure ensures that you gain in-depth knowledge of the subject matter and build practical lab skills tailored to that semester’s objectives. It’s a unique opportunity to be part of cutting-edge cancer therapeutic development while gaining experience in a multidisciplinary biotech setting.

Selected relevant publications:

  • Fu Z, Li S, Han S, et al (2022). Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy, 7(93). doi: 10.1038/s41392-022-00947-7

Additional application required

You must submit an additional application through the Online Registration portal.

All application materials must be submitted on the following dates by midnight in your time zone:

  • November 1 for spring semester applicants
  • May 1 for fall semester applicants

Complete your application through Student Registration.

Syllabus

The syllabus for this course is currently under development. A draft syllabus will be posted here as soon as it is available.

Faculty

Coming Soon

Faculty

The faculty teaching this course will be listed here soon.

Research Assistantship FAQ

Learn more about research at DIS.